Serial radiation therapy is safe and effective as alternative treatment to systemic therapy for kidney cancer
In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy is a safe and effective noninvasive treatment for oligometastatic renal cell carcinoma (RCC). The findings were published today in The Lancet Oncology.
Led by Chad Tang, M.D., assistant professor of Radiation Oncology, the MD Anderson RCC Oligometastasis Phase II trial is the first study to...
MD Anderson Research Highlights: ASTRO 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
MD Anderson’s Boot Walk to End Cancer® to unite thousands virtually on Nov. 6
The University of Texas MD Anderson Cancer Center celebrates its sixth annual Boot Walk to End Cancer® on Saturday, Nov. 6. Due to ongoing...
MD Anderson Research Highlights for October 20, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targeted therapy approaches for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), predicting survival following follicular lymphoma treatment, understanding how AML responds to checkpoint...
Anil Sood, M.D., elected to the National Academy of Medicine
Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine, has been elected to the National Academy of Medicine (NAM) for...
MD Anderson welcomes 28 new leaders to Board of Visitors, honors new Life Members
The University of Texas MD Anderson Cancer Center welcomed 28 new members to its Board of Visitors (BOV) with the start of a new fiscal year...
ATR inhibitor RP-3500 demonstrates safety and early clinical benefit
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500...
MD Anderson and Schrödinger announce strategic research collaboration to accelerate development of WEE1 program
The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration...
MD Anderson Research Highlights for October 6, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...